Stock Forecast Chart
Stock Price Prediction Summary
Forecast Score Based on 2 Weeks
Based on our forecast, the price of AGE will rise by +33.65% over the next 2 Weeks and hit $14.84 by Tuesday, April 9, 2024. In that time frame, AGE's share price is expected to range between $12.52 and $17.08.
BearishAverageBullishAGE shares fell -11.90% in Tuesday, March 26, 2024's trading session, dropping from a previous close of $12.60 to move at $11.10. The stock demonstrated notable intraday movement (see AGE's key stats for a full breakdown), fluctuating between $11.10 and $12.59, a +13.42% trading range. While recent weeks have seen some volatility, AGE has managed to secure a -24.85% drop over the past 2 weeks. The downward price movement was accompanied by decreased trading volume, with approximately 3.68K shares changing hands, 683 fewer than the previous session. This amounted to $40.86K in total market activity.
Will AGE Continue Its Upward Trend?
According to analyst ratings and projections for AGE, AgeX Therapeutics, Inc. shares are anticipated to increase by +35.06%, potentially reaching $17.09 per share by April 9, 2024. Short-term technical indicators currently suggest a bullish sentiment for AGE. However, the stock has recorded 19 negative trading days within the past 30 sessions. Based on the AGE stock forecast, now is a good time to buy AGE stock because its current trading price is -25.18% below our predicted value, hinting at a possible overvaluation. For deeper insights, view our sentiment analysis on AGE covering social and institutional perspectives.
AGE Technical Momentum: Overbought, Oversold, or Neutral?
An analysis of Relative Strength Index (RSI) indicators provides insight into AGE's momentum. Short-term RSIs (9, 14, and 20-day figures ranging from 37.34% to 42.95%) suggest mixed signals, with the stock in a neutral to slightly bearish momentum phase. The 50-day RSI, at 44.92%, suggests a neutral medium-term outlook. Additionally, the 100-day RSI, at 46.06%, maintains a neutral outlook for the long term. Insights into AGE's shareholder base show how institutional investors are positioning themselves during these momentum shifts
AgeX Therapeutics, Inc. Monthly Forecast 2024–2025
September 2024
According to our latest forecast models, AgeX Therapeutics, Inc. (AGE) is positioned to show a strong performance in September 2024. The price is predicted to move between $14.77 and $38.39, settling at an average of $27.20. This could translate to a +145.05% gain.
October 2024
Based on current market signals, AgeX Therapeutics, Inc. is projected to trend october 2024. We forecast a trading range from $11.60 to $65.67, with a likely average price of $30.81. Investors could expect a potential return of +177.57%.
November 2024
Our predictive algorithms indicate AgeX Therapeutics, Inc. stock may see a shift in November 2024. The expected range spans $6.68–$48.32, with an average target of $29.60. This represents a positive outlook and a possible gain of +166.67%.
December 2024
Analyzing established trends, AgeX Therapeutics, Inc. looks set to move in December 2024. Projections place the stock between $10.02 and $45.40, averaging around $26.69. This suggests a +140.45% gain from current levels.
January 2025
Market indicators suggest AgeX Therapeutics, Inc. could experience notable changes during January 2025. Prices could fluctuate within $16.64 to $44.52, with a midpoint forecast of $29.34. The stock might deliver a +164.32% gain.
February 2025
Forecasting for February 2025, models estimate that AgeX Therapeutics, Inc. may undergo key fluctuations. If trends hold, the stock might trade between $22.65 and $68.49, averaging $43.66. This signals a positive trajectory with potential returns around +293.33%.
March 2025
According to our latest forecast models, AgeX Therapeutics, Inc. (AGE) is positioned to show a strong performance in March 2025. The price is predicted to move between $24.66 and $65.18, settling at an average of $38.98. This could translate to a +251.17% gain.
AGE's history of dividends and stock splits also plays a role in long-term investor confidence.